Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,955 total articles
Coffee Holding (JVA) punched up ~18% to $3.73 on heavy volume as the market priced in materially improved near-term prospects. At ~ $18.1M market cap, the stock trades at a P/E near 13, P/B ~0.66 and EV/EBITDA ~8.2 - cheap for a cash-generating roaster with low leverage. I rate JVA Strong Buy for a mid-term swing: entry $3.73, target $5.63 (52-week…
We reaffirm a Buy on Alcon (ALC). The STAAR merger setback is a headline, not a thesis-breaker: Alcon’s core Surgical and Vision Care franchises generate durable cash flow, the balance sheet is conservative, and a pending LENSAR deal plus broad ophthalmic market growth create upside catalysts. Technicals look oversold — present an entry — but the t…
Palvella’s QTORIN topical platform is targeting multiple rare dermatologic and vascular malformations with no FDA-approved therapies. Recent positive Phase 2 data, a completed upsized $230M offering and a small public float create a volatile but actionable setup. This trade proposes a long position at current levels with a defined stop and upside t…
Sonoco (SON) looks attractive as a mid-term long trade: low valuation (P/E ~5.2), solid free cash flow and announced April price increases in paperboard create a clear earnings upside. Entry $53.70, stop $50.00, target $63.00 over ~45 trading days.
UnitedHealth ($UNH) is showing technical signs of stabilization after a difficult 2025. Fundamentals still look solid - market cap about $259B, free cash flow roughly $17.4B and EV/EBITDA near 10 - but regulatory and cost pressures leave upside capped until execution visibly improves. This trade idea outlines a guarded, short-biased swing to captur…
Zeta's acquisition of Marigold gives the company more addressable data and product depth at a reasonable enterprise value. The combination improves near-term cash generation and raises the upside for a mid-term trade. Entry at $17.90, stop at $16.25, target $22.50 — mid-term (45 trading days) thesis with a medium risk profile.
PPC sits close to its 52-week low with a sub-8x P/E, healthy free cash flow and a growing prepared-foods franchise. Technicals show oversold conditions and elevated short activity, offering a defined-risk long setup. This is a mid-term trade (45 trading days) aiming for mean reversion toward the 50-day band while keeping downside protection tight.
UnitedHealth Group ($UNH) trades at a valuation that discounts much of the company's Optum-driven long-term optionality. With free cash flow of $17.37B, an enterprise value of roughly $309B, and EV/EBITDA near 10x, the risk/reward favors accumulation. This trade idea lays out an entry at $285.86, a stop at $250.00, and a 180-day target of $360.00 a…
Aya Gold & Silver looks undervalued relative to its earnings profile and near-term production growth. This trade idea outlines a disciplined long with clear entry at $4.50, a stop at $3.20, and staged upside targets to capture both a re-rating and operational execution into higher-margin ounces.
UnitedHealth ($UNH) is a beaten-down market leader trading near $285.50 with a market cap of about $259.1B. The core thesis: Optum's accelerated adoption of predictive analytics, workflow automation, and pharmacy management AI can materially restore margins and free cash flow, creating an asymmetric reward-to-risk trade over the next 45 trading day…
American Outdoor Brands (AOUT) trades like a small-cap beaten down by inventory/tariff noise and headline risk, but the business still shows margin resiliency, no debt and a sub-$110M market cap. This trade buys a tactical pullback with a defined stop and a mid-term target that captures rerating potential if sales normalize and guidance is reinstat…
Ares Management (ARES) just went ex-dividend with a meaningful payout bump and has been adding assets via M&A, lifting AUM toward record levels. The stock trades near $101 after a sharp sector-wide selloff tied to AI and private-credit jitters. With FCF north of $4.4B, a manageable P/E in the high 30s, and an immediate yield of roughly 4.4%, this i…
MP Materials controls critical U.S. rare-earth supply at Mountain Pass and is transitioning from a miner to an integrated producer of refined oxides and magnet precursors. The balance sheet supports growth, but the stock already carries a premium. This trade idea lays out an entry at $59.50, a $80 target and a $50 stop, sized for a mid-term swing (…
Credo Technology is printing revenue growth few hardware names can match and commanding enterprise-level margins from its Active Electrical Cables and SerDes chiplets. At $118, the market is assigning a premium multiple but is still underestimating near-term revenue compounding and product-led margin expansion. This trade targets a run toward $190 …
We initiate a tactical long on ZLB:CA, entering at $8.50 with a $11.25 target and a $6.75 stop. The thesis: ZLB's diversified equity mix (resources + domestic-oriented holdings + cash-generative assets) can outperform in periods of geopolitical stress as investors favor balance-sheet strength and commodity exposure. Trade horizon: mid term (45 trad…
DSV's scale, cash generation profile and history of folding acquisitions into earnings creates a 'spring-loaded' setup: a near-term pullback and low visible volatility leave optionality for an M&A-fueled rerating. This trade targets a measured entry with clear stop and upside tied to deal-driven revaluation.
Boyd Gaming (BYD) trades at a low multiple relative to cash flow and peers, while incremental wins in online and racing operations create a playbook for international expansion. This trade idea outlines a swing-long entry with clear targets, stop, catalysts and risks tied to execution and macro sensitivity.
Incyte trades at a roughly $18.5B market cap with solid free cash flow and low leverage. Recent clinical noise has pressured the stock into the mid-$90s, creating a defined risk/reward for a swing trade into 2026 readouts and commercial updates. This plan buys a post-pullback entry, limits downside with a clear stop, and targets recapture toward pr…
Carlyle (CG) is getting punished largely on fears around private credit liquidity and mark-to-market pressure. Those concerns look priced in: Carlyle trades at a reasonable valuation (EV/EBITDA ~8.8), yields ~3.1%, generates ~$1.48B of free cash flow and carries modest leverage (debt/equity ~0.52). I upgrade to Buy and lay out an entry at $46.38, a…
CoreWeave is scaling into one of the largest specialized AI cloud providers. After 168% revenue growth in 2025 and a $66.8B backlog, the company is trading well below its long-term upside if it executes. This trade is for disciplined contrarians: buy near $86.46, stop at $65, target $150 across a 180 trading-day horizon, and size accordingly given …
Amneal's stock has pulled back from its 52-week high as near-term revenue growth looks muted. The balance sheet oddities and high P/E are real, but $270M in free cash flow, an EV/EBITDA near 9.9, and two high-impact pipeline opportunities (CREXONT and an omalizumab biosimilar) make a structured long trade attractive for the mid-term trader.
SoFi offers a high-conviction trade setup after CEO Anthony Noto's $1M stock purchase and a deepened Mastercard partnership for SoFiUSD. Fundamentals show rapid customer and revenue growth, improving profitability, but the stock still trades at a premium to last year's fundamentals. This idea lays out an entry, stop, targets and the reasons to own …
CTMX popped to a 52-week high on massive volume as investors price in clearer evidence that CytomX's Probody platform is delivering conditionally activated activity in tumors. Fundamentals remain mixed, but the technical breakout, rising short-covering, and upcoming clinical readouts make a disciplined long trade attractive for a mid-term swing.
Sterling Infrastructure rallied after a strong quarter and continues to look like a solid pick-and-shovel play into data center and transportation buildouts. Healthy free cash flow, low leverage, and a pivot toward higher-margin e-infrastructure work support upside, while valuation is rich but not extreme for a growth-infrastructure story. Trade pl…
Eledon Pharmaceuticals' anti-CD40L antibody tegoprubart (AT-1501) is showing meaningful clinical momentum as a potential alternative to calcineurin inhibitors in kidney transplantation. With positive Phase 2 BESTOW data, real-world use in a genetically modified pig kidney transplant, and a strengthened balance sheet from a $57.5M financing, ELDN lo…
